Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field.
Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field.
复制标题
DOI：
10.3390/jcm7030041
复制
发表时间：
2018-03-02
影响因子：
3.9
通讯作者：
Williams JA
中科院分区：
文献类型：
--
作者：
Williams JA
自免疫缺陷小鼠的发展取得突破性进展以来，创造患者来源的异种移植物(PDX)的能力已经有了相当大的进步。在药物发现中，研究人员如何利用某些癌症类型的PDX也发生了变化，从传统上选择几个模型来描述药物，到选择通过筛选广泛的肿瘤模型来评估肿瘤间反应的异质性，并随后实现临床分层策略。与所有模型和方法一样，这种方法的缺陷是显而易见的，我们对这些模型的保真度的理解继续扩大。然而，到目前为止，它们仍然被视为肿瘤学中最忠实的建模系统之一。目前，正在进行许多努力来增加PDX的实用性和可译性，包括引入一种人类免疫成分来进行免疫治疗研究。
The ability to create patient derived xenografts (PDXs) has evolved considerably from the breakthrough of the development of immune compromised mice. How researchers in drug discovery have utilized PDX of certain cancer types has also changed from traditionally selecting a few models to profile a drug, to opting to assess inter-tumor response heterogeneity by screening across a broad range of tumor models, and subsequently to enable clinical stratification strategies. As with all models and methodologies, imperfections with this approach are apparent, and our understanding of the fidelity of these models continues to expand. To date though, they are still viewed as one of the most faithful modeling systems in oncology. Currently, there are many efforts ongoing to increase the utility and translatability of PDXs, including introducing a human immune component to enable immunotherapy studies.
登录
查看更多内容
影响因子：
82.9
作者：
Gao, Hui;Korn, Joshua M.;Sellers, William R.
通讯作者：
Sellers, William R.
影响因子：
64.5
作者：
Gao D;Vela I;Sboner A;Iaquinta PJ;Karthaus WR;Gopalan A;Dowling C;Wanjala JN;Undvall EA;Arora VK;Wongvipat J;Kossai M;Ramazanoglu S;Barboza LP;Di W;Cao Z;Zhang QF;Sirota I;Ran L;MacDonald TY;Beltran H;Mosquera JM;Touijer KA;Scardino PT;Laudone VP;Curtis KR;Rathkopf DE;Morris MJ;Danila DC;Slovin SF;Solomon SB;Eastham JA;Chi P;Carver B;Rubin MA;Scher HI;Clevers H;Sawyers CL;Chen Y
通讯作者：
Chen Y
DOI：
10.1073/pnas.89.12.5645
发表时间：
1992-06-15
影响因子：
11.1
作者：
FU, XY;GUADAGNI, F;HOFFMAN, RM
通讯作者：
HOFFMAN, RM
影响因子：
11.2
作者：
Daniel VC;Marchionni L;Hierman JS;Rhodes JT;Devereux WL;Rudin CM;Yung R;Parmigiani G;Dorsch M;Peacock CD;Watkins DN
通讯作者：
Watkins DN
DOI：
10.1158/1541-7786.mcr-15-0189
发表时间：
2016-01
期刊：
Molecular cancer research : MCR
影响因子：
--
作者：
Goodspeed A;Heiser LM;Gray JW;Costello JC
通讯作者：
Costello JC